


# BC-2059

**ALTERNATE NAME:** Tegatrabetan  
N-[3,6-bis[[[(3R,5S)-3,5-dimethylpiperidin-1-yl]sulfonyl]-10-nitrosoanthracen-9-yl]hydroxylamine

**CATALOG #:** B3396-5 5 mg  
B3396-25 25 mg

**STRUCTURE:**



**MOLECULAR FORMULA:** C<sub>28</sub>H<sub>36</sub>N<sub>4</sub>O<sub>6</sub>S<sub>2</sub>

**MOLECULAR WEIGHT:** 588.74

**CAS NUMBER:** 1227637-23-1

**APPEARANCE:** Solid

**PURITY:** ≥98%

**SOLUBILITY:** >50 mg/ml DMSO

**DESCRIPTION:** BC-2059 is a potent inhibitor of the Wnt/beta-catenin pathway with potential antineoplastic activity. BC-2059 binds to transducin beta-like protein 1 (TBL1) and disrupts the binding of beta-catenin to TBL1. This promotes beta-catenin degradation, attenuates nuclear and cytoplasmic levels of beta-catenin, and reduces transcriptional activity of transcription factor 4 (TCF4) and expression of its target genes, cyclin D1, c-Myc and survivin.

**STORAGE TEMPERATURE:** -20°C. Protect from light

**HANDLING:** Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

**RELATED PRODUCTS:**

IQ-1 (1663)  
Adavivint (B2437)  
CCT-251545 (B2501)  
ICG-001 (2275)  
iCRT14 (B2562)

**DISCLAIMER:** *FOR RESEARCH USE ONLY! Not to be used on humans.*